Advertisement

AstaZeneca warns over expiring patents as net profit falls 37 per cent to $6.3B

LONDON – Anglo-Swedish pharmaceutical company AstraZeneca PLC warned over expiring patents on its medicines as the company announced a 37 per cent fall in full-year net profit.

AstraZeneca said that its net profit fell to $6.3 billion in the year ended Dec. 31, compared with nearly $10 billion in 2011. The company blamed the loss of exclusivity on several big-name drugs for a drop in revenue to $28 billion from $33.6 billion a year earlier.

Get expert insights, Q&A on markets, housing, inflation, and personal finance information delivered to you every Saturday.

Get weekly money news

Get expert insights, Q&A on markets, housing, inflation, and personal finance information delivered to you every Saturday.
By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy.

In one example, U.S. revenue fell 21 per cent, largely due to competition from generic versions of AstraZeneca’s anti-depression medication Seroquel IR.

Chief executive Pascal Soriot said Thursday the company’s 2012 performance “reflects a period of significant patent expiry and tough market conditions.”

He said the company’s new leadership team would focus on the company’s brands and product pipeline.

Advertisement

Sponsored content

AdChoices